诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

交易中 07-08 13:23:57 EDT

155.70

-1.33

-0.85%

最高156.36	最低155.13	成交量83.03万
今开155.39	昨收157.03	日振幅0.78%
总市值2,971亿	流通市值2,828亿	总股本19.08亿
成交额1.29亿	换手率0.05%	流通股本18.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":155.7,"timestamp":1783531436458,"preClose":157.03,"halted":0,"volume":830284,"delay":0,"changeRate":-0.008469719161943657,"floatShares":1816000000,"shares":1907999999,"eps":6.980982,"marketStatus":"交易中","change":-1.33,"latestTime":"07-08 13:23:57 EDT","open":155.39,"high":156.3611,"low":155.1325,"amount":129218169.98636,"amplitude":0.007824,"askPrice":155.75,"askSize":2,"bidPrice":155.68,"bidSize":2,"shortable":3,"etf":0,"ttmEps":6.980982,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783540800000},"marketStatusCode":2,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":157.03,"dividendRate":0.029969,"preHourTrading":{"tag":"盘前","latestPrice":155.35,"preClose":157.03,"latestTime":"09:29 EDT","volume":5000,"amount":777025.2999999999,"timestamp":1783517399130,"change":-1.68,"changeRate":-0.010699,"amplitude":0.004493},"postHourTrading":{"tag":"盘后","latestPrice":150,"preClose":157.03,"latestTime":"19:21 EDT","volume":7049,"amount":1105571.0672,"timestamp":1783466493597,"change":-7.03,"changeRate":-0.044769,"amplitude":0.044769},"volumeRatio":0.802258,"impliedVol":0.2919,"impliedVolPercentile":0.9522},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"1181290052","title":"异动解读｜诺华盘后下跌4.48%，中国集采伪造签名风波叠加大额并购引发抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1181290052","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181290052?lang=zh_cn&edition=full","pubTime":"2026-07-08 04:07","pubTimestamp":1783454845,"startTime":"0","endTime":"0","summary":"7月7日，诺华盘后下跌4.48%，报157.03美元/股，成交额108.69万美元。消息面上，中国国家医保局披露某进口原研药企在第12批集采中提交伪造专家建议函，80%以上签名不实，业内传闻涉事企业为诺华。诺华随后回应称所指企业并非诺华。此外，诺华此前宣布以最高15亿美元收购英国生物技术公司Myricx Bio，叠加今年已累计达成的Excellergy（20亿美元）、Antares（19亿美元）等多项并购交易，频繁的资本支出持续对股价形成压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649938611","title":"国家医保局披露有药企在集采中伪造医生联名函 诺华回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2649938611","media":"中国新闻网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649938611?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:09","pubTimestamp":1783429791,"startTime":"0","endTime":"0","summary":"中新网北京7月7日电(记者赵方园)7月7日晚间，国家医保局发布风险提示，在第12批国家组织药品集中带量采购(以下简称“第12批集采”)确定采购品种阶段，某进口原研药企业提交了所谓“31家医院78名医生联署的专家建议函”，试图以此影响集采定品。经向“署名专家”本人逐一查证，80%以上签名不真实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607073797002182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607073797002182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","IE00B4R5TH58.HKD","LU0320765489.SGD","BK4007","BK4588","LU0211331839.USD","IE00B2B36J28.USD","NVS","BK4532","IE00BJT1NW94.SGD","LU0070302665.USD","PPH","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","MEDX","LU0208291251.USD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173097512","title":"异动解读｜诺华盘中下跌3.05%，斥资15亿美元收购Myricx Bio引发市场抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1173097512","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173097512?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:10","pubTimestamp":1783347038,"startTime":"0","endTime":"0","summary":"7月6日，诺华盘中下跌3.05%，报155.055美元/股，成交额1.02亿美元。消息面上，诺华宣布已就收购英国生物技术公司Myricx Bio达成协议，交易总对价最高可达15亿美元，其中包括11亿美元预付款及最高4亿美元里程碑付款。值得注意的是，诺华近期并购动作频繁。诺华是一家创新医药公司，专注于心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学等核心治疗领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649137647","title":"从“旁观者”到“追赶者”：诺华(NVS.US)斥资15亿美元收购Myricx，ADC赛道再落关键一子","url":"https://stock-news.laohu8.com/highlight/detail?id=2649137647","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649137647?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:02","pubTimestamp":1783328521,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华已就收购英国生物技术企业Myricx Bio达成协议，交易总对价最高可达15亿美元。据诺华周一发布声明，Myricx股东将获得11亿美元预付款，以及最高4亿美元的潜在里程碑付款。2025年10月，诺华以120亿美元收购了Avidity Biosciences，成为当年规模最大的抗体相关交易。此次收购Myricx，正是其深耕肿瘤学核心领域、充实ADC管线的关键落子。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","NVS","IE00BFTCPJ56.SGD","LU0320765489.SGD","BK4578","BK4231","BK4007","NETL","BK4532","LU0070302665.USD","LU0208291251.USD","IE0002141913.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","PPH","BK4585","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4080","BK4588","IE00B4R5TH58.HKD","LU0211331839.USD","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649436986","title":"诺华同意以最高15亿美元收购Myricx bio。","url":"https://stock-news.laohu8.com/highlight/detail?id=2649436986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649436986?lang=zh_cn&edition=full","pubTime":"2026-07-06 13:05","pubTimestamp":1783314340,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","BK4588","IE00B4R5TH58.HKD","LU0208291251.USD","IE0002141913.USD","LU0211331839.USD","BK4585","MEDX","BK4532","BK4007","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4578","IE00BJT1NW94.SGD","PPH","IE0009355771.USD","NVS","LU0320765489.SGD","LU0070302665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191800911","title":"异动解读｜诺华盘中上涨3.01%，脊髓性肌萎缩症基因疗法获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1191800911","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191800911?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:11","pubTimestamp":1783001484,"startTime":"0","endTime":"0","summary":"7月2日，诺华盘中上涨3.01%，报158.85美元/股，成交额4862.01万美元。消息面上，诺华宣布其基因替代疗法Itvisma获得欧盟委员会批准，用于治疗2岁及以上脊髓性肌萎缩症（SMA）患者。该疗法为单次给药，通过替代缺陷SMN1基因改善患者运动功能，无需基于体重或年龄调整剂量。审批主要依据III期临床试验数据，患者在52周观察期内运动功能获得统计学显著改善。此前4月该疗法已获欧洲药品管理局CHMP推荐，本次正式获批标志着诺华在罕见病基因治疗领域的商业化进程再进一步。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646876875","title":"中金公司给予默沙东“跑赢行业”评级，目标价138美元；中信建投给予诺华制药“买入”评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646876875","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646876875?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:24","pubTimestamp":1782379489,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1989772840.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","NVS","LU0965509101.SGD","LU0266013472.USD","LU1941712348.USD","LU1069347547.HKD","UUP","LU1571399168.USD","LU1023059063.AUD","LU1162221912.USD","LU2125154935.USD","LU1929549753.HKD","LU2491050154.USD","LU0289739699.SGD","LU2089984988.USD","LU1923622614.USD","LU0122379950.USD","LU0868494708.USD","LU2324357040.USD","BK4559","LU2361045086.USD","SG9999001176.SGD","LU1934455863.HKD","LU1116320901.HKD","LU2433249047.HKD","LU0320765489.SGD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU0098860793.USD","LU1201861249.SGD","IE00B1BXHZ80.USD","SG9999014559.SGD","LU2461242641.AUD","BK4550","LU0265550946.USD","LU1066051811.HKD","SG9999013999.USD","LU2357627491.SGD","LU1037948897.HKD","LU2023250504.SGD","IE00BN8TJ469.HKD","SG9999001176.USD","SG9999002224.SGD","BK4585","MRK","UDN","LU0320765646.SGD","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645813551","title":"诺华与Antares签署价值高达19亿美元的抗癌药物协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2645813551","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645813551?lang=zh_cn&edition=full","pubTime":"2026-06-24 20:45","pubTimestamp":1782305121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","IE00BJT1NW94.SGD","LU0208291251.USD","NVS","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","LU0320765489.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0070302665.USD","BK4588","IE00B4R5TH58.HKD","BK4585","BK4007","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158765344","title":"异动解读｜诺华盘中上涨3.01%，抗体偶联小核酸药物早期临床数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1158765344","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158765344?lang=zh_cn&edition=full","pubTime":"2026-06-24 03:59","pubTimestamp":1782244772,"startTime":"0","endTime":"0","summary":"6月24日，诺华盘中上涨3.01%，报153.41美元/股，成交额1.92亿美元。消息面上，诺华宣布其抗体偶联寡核苷酸药物del-brax的1/2期研究达到主要终点和关键次要终点，表明该疗法在面肩肱型肌营养不良症患者中实现了强有力的靶点结合并减少了肌肉损伤。Del-brax是诺华通过收购获得的三款潜在First-in-class疗法之一，另两款分别针对1型强直性肌营养不良症和杜氏肌营养不良症。诺华所在的制药行业中，默沙东涨3.66%，强生涨3.6%，诺和诺德涨3.3%，礼来涨0.76%，辉瑞跌1.34%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643756361","title":"摩根大通：生物药企融资回暖 大型药企行业并购优先级高于独立IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756361","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643756361?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:21","pubTimestamp":1781605294,"startTime":"0","endTime":"0","summary":"多数本土生物科技企业采取双轨策略，同步筹备 IPO、对接药企收购资源，不少企业上市落地前完成并购交割。头部药企偏好数十亿美金中型补充式并购，近期葛兰素史克斥资 106 亿美元收购肿瘤药企 Nuvalent，打破中小型并购定价惯例。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301588","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","IE00BYXW3230.USD","LU0640476718.USD","LU1496350502.SGD","LU1894683348.USD","JPMO","LU0964807845.USD","LU2357305700.SGD","LU1366192091.USD","LU0265550946.USD","IE00B3S45H60.SGD","LU0215105999.USD","LU1548497426.USD","IE0009355771.USD","IPOS","GSK.UK","LU0942090050.USD","LU2505996509.AUD","IE00BJJMRZ35.SGD","LU0976567544.SGD","BK4504","LU0238689110.USD","159839","LU1064131342.USD","LU1629891620.HKD","IE00B2B36J28.USD","LU0345769128.USD","LU0211331839.USD","JPM","SG9999002224.SGD","IE0034235303.USD","IE00BKDWB100.SGD","LU0820562030.AUD","LU2357627491.SGD","JPO","LU0251132253.USD","JPX","LU0689472784.USD","NVS","LU2592432038.USD","LU0070302665.USD","GSK","LU0310799852.SGD","BK4578","IE00B1XK9C88.USD","LU2237443622.USD","LU2211815571.USD","BK4566","PGF","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119078937","title":"异动解读｜诺华盘前上涨3.11%，多项管线利好密集释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1119078937","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119078937?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:47","pubTimestamp":1781178451,"startTime":"0","endTime":"0","summary":"6月11日，诺华盘前上涨3.11%，报152.71美元/股，成交额113.54万美元。消息面上，诺华近期利好密集：公司宣布其肌营养不良实验性疗法del-brax的I/II期研究达到主要终点及关键次要终点；同日，诺华与Orionis Biosciences达成总额超14亿美元的分子胶药物合作；此外，泰菲乐联合迈吉宁新增适应症获中国国家药监局批准，用于BRAF V600E突变阳性的分化型甲状腺癌治疗。多重管线进展叠加，提振市场对公司研发管线价值的预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440345","title":"诺华泰菲乐联合迈吉宁新适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440345","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642440345?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:13","pubTimestamp":1781086380,"startTime":"0","endTime":"0","summary":"南方财经6月10日电，诺华公司今日宣布，其双靶向联合治疗药物泰菲乐?（甲磺酸达拉非尼胶囊）联合迈吉宁?（曲美替尼片），于日前获国家药品监督管理局批准新增适应症，用于治疗BRAFV600E突变阳性、放射性碘难治或不适用、且血管内皮生长因子酪氨酸激酶抑制剂（VEGFR-TKI）治疗失败的局部晚期或转移性分化型甲状腺癌成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766815757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0070302665.USD","BK4585","LU0211331839.USD","LU0208291251.USD","IE00B4R5TH58.HKD","BK4007","BK4578","BK4588","IE0009355771.USD","LU0320765489.SGD","BK4532","IE00B2B36J28.USD","NVS","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169307619","title":"异动解读｜诺华盘中上涨3.13%，Cosentyx三期试验数据积极叠加板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1169307619","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169307619?lang=zh_cn&edition=full","pubTime":"2026-06-05 03:21","pubTimestamp":1780600897,"startTime":"0","endTime":"0","summary":"6月5日，诺华盘中上涨3.13%，报148.15美元/股，成交额2.74亿美元。消息面上，诺华近日公布其核心产品Cosentyx在多发性风湿性肌痛（PMR）三期临床试验中的最新数据，显示该药物在持续缓解率方面相较对照组取得了具有统计学意义和临床意义的显著差异。此外，诺华在ASCO年会上公布的新型放射性药物治疗前列腺癌的早期临床数据亦表现强劲，为公司管线增添增长预期。板块方面，制药行业整体走强，个股中默沙东涨4.57%，诺和诺德涨4.26%，礼来涨4.13%，强生涨2.24%，辉瑞涨1.38%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186950476","title":"异动解读｜诺华盘中下跌3.06%，报145.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186950476","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186950476?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:14","pubTimestamp":1780323242,"startTime":"0","endTime":"0","summary":"6月1日，诺华盘中下跌3.06%，报145.04美元/股，成交额4396.47万美元。诺华所在的制药行业中，板块整体承压，个股中，施贵宝跌3.33%，默沙东跌2.75%，礼来跌2.19%，辉瑞跌1.91%，强生跌1.66%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089097","title":"博腾股份斯洛文尼亚项目陷争议 诺华索赔5470万欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089097","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635089097?lang=zh_cn&edition=full","pubTime":"2026-05-15 19:36","pubTimestamp":1778845013,"startTime":"0","endTime":"0","summary":"5月13日，博腾股份（300363.SZ）公告披露，其位于斯洛文尼亚的研发生产基地项目与Novartis（简称“诺华”）产生重大争议。诺华方面要求其在90天内搬离并保留合计约5470万欧元（约合人民币4.3亿元）的索赔权。博腾股份表示不认可诺华主张，公司及斯洛文尼亚项目全资子公司PSI尚未收到诺华已提起正式诉讼程序的通知。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739110668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B2B36J28.USD","BK4578","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","FXE","BK0028","LU0208291251.USD","BK4588","BK4007","300363","LU0070302665.USD","LU0211331839.USD","NVS","BK4532","BK4585","IE00BJT1NW94.SGD","BK0239","LU0320765489.SGD","IE0009355771.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722124","title":"累计投入4.48亿元 博腾股份欧洲研发生产基地遭诺华解约","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722124","media":"中国经营报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635722124?lang=zh_cn&edition=full","pubTime":"2026-05-15 07:27","pubTimestamp":1778801222,"startTime":"0","endTime":"0","summary":"5月13日，博腾股份（300363.SZ）披露，其位于斯洛文尼亚的研发生产基地遭到诺华公司（Novartis）的单方面解约，诺华公司要求其在90天内搬离。历史公告显示，这个研发生产基地是博腾股份在欧洲布局的首个研发生产基地，投资金额为5000万欧元（当时折合人民币约3.5亿元）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153737904337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BJJMRZ35.SGD","LU0211331839.USD","BK4585","LU0208291251.USD","300363","LU0320765489.SGD","BK0028","IE00BFTCPJ56.SGD","LU0070302665.USD","BK0239","IE00BJT1NW94.SGD","BK4588","IE0002141913.USD","BK4578","IE0009355771.USD","BK4532","BK4007","IE00B4R5TH58.HKD","NVS","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635794643","title":"股价跌停！博腾股份海外项目遭诺华单方面解约","url":"https://stock-news.laohu8.com/highlight/detail?id=2635794643","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635794643?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:09","pubTimestamp":1778746140,"startTime":"0","endTime":"0","summary":"5月13日晚间，国内领先的合同研发生产组织（CDMO）博腾股份（300363.SZ）的一纸公告，为其筹划近四年的欧洲市场布局蒙上了一层厚重的阴霾。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143737441846.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737441846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4578","300363","IE00B4R5TH58.HKD","IE0009355771.USD","BK0028","LU0208291251.USD","BK4007","BK4588","IE0002141913.USD","LU0211331839.USD","LU0070302665.USD","IE00BFTCPJ56.SGD","BK4585","IE00B2B36J28.USD","LU0320765489.SGD","BK4532","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119830","title":"跨国药企业绩大爆发，集体加仓中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119830","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119830?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:19","pubTimestamp":1778141940,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　2026年第一季度，全球制药巨头的业绩版图再度刷新。　　有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。默沙东与其他跨国药企一道，已将“加注中国创新”视为战略性防御与进攻并存的长期解法。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0203345920.USD","LU2468319806.SGD","LU1023059063.AUD","BK4585","IE00B4R5TH58.HKD","LU1066051498.USD","LU2089984988.USD","LU1989772923.USD","BK4588","IE00BBT3K403.USD","IE00B2B36J28.USD","LU1037948541.HKD","LU1699723380.USD","LU1430594728.SGD","LU0266013472.USD","LU0154236417.USD","LU1037948897.HKD","LU1057294990.SGD","LU1983299246.USD","SG9999002224.SGD","IE00BLSP4239.USD","LU1989772840.SGD","IE00BLSP4452.SGD","BK4599","LU0965509283.SGD","MRK","LU0203347892.USD","LU0234572021.USD","LU1934455863.HKD","LU0106261372.USD","LU2361044865.SGD","IE00BKVL7J92.USD","LU1066053197.SGD","LU0942090050.USD","LU1116320901.HKD","NVO","LU1093756168.USD","EURmain","SG9999014559.SGD","LU1989771016.USD","LU2324357040.USD","SG9999001440.SGD","IE00BN8TJ469.HKD","SG9999014567.USD","LU2023250504.SGD","SG9999015358.SGD","LU2491050154.USD","SG9999014575.USD","NVOH","LU1061106388.HKD","LU2360032135.SGD","LU2125154778.USD","IE00BZ1G4Q59.USD","IE000M9KFDE8.USD","LU1066051811.HKD","FXE","LU0965509010.AUD","LU0859254822.USD","BMY","LU0477156953.USD","LU0868494708.USD","SG9999014542.SGD","IE00BJJMRZ35.SGD","LLY","LU1116320737.USD","LU0289739699.SGD","LU2461242641.AUD","LU0965508806.USD","IE0009355771.USD","LU0208291251.USD","LU0130517989.USD","LU1941712264.USD","LU2361044949.HKD","SG9999002232.USD","IE00BSNM7G36.USD","LU1917777945.USD","EUO","LU0122379950.USD","LU0320765646.SGD","LU0006306889.USD","LU0985320562.USD","LU2023250843.SGD","LU2491050071.SGD","NVOX","LU2106854487.HKD","LU0058720904.USD","LU1571399168.USD","SG9999015341.SGD","AZN","LU0098860793.USD","LU1585245621.USD","BK4532","LU0265550359.USD","BK4559","LU1035773651.USD","LU1934455277.USD","LU2491049909.HKD","LU0130102774.USD","LU0861579265.USD","LU0980610538.SGD","LU0070302665.USD","SGXZ57979304.SGD","LU1066051225.USD","LU1162221912.USD","BK4533","SG9999001176.USD","LU1069347547.HKD","LU0965509101.SGD","SG9999001176.SGD","LU0265550946.USD","LU0320765489.SGD","BK4007","BK4550","LU1929549753.HKD","LU0211331839.USD","LU1934455194.USD","LU2112291526.USD","LU0648001328.SGD","NVS","BK4516","LU1974910355.USD","SG9999013999.USD","LU0868494617.USD","LU1201861249.SGD","IE00BJT1NW94.SGD","BK4534","LU1291159041.SGD","LU2125154935.USD","LU2361045086.USD","LU2357627491.SGD","LU0432979614.USD","IE0002141913.USD","SNY","LU1941712348.USD","IE00BFTCPJ56.SGD","LU1093756325.SGD","LU0238689110.USD","MEURmain","IE00B1BXHZ80.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145136092","title":"诺华Q1销售净额131.1亿美元，不及市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1145136092","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145136092?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:50","pubTimestamp":1777355455,"startTime":"0","endTime":"0","summary":"4月28日，$诺华(NVS)$夜盘跌超3%！第一季度销售净额131.1亿美元，市场预估133.6亿美元；第一季度核心净利润37.9亿美元，市场预估39.9亿美元；第一季度核心运营利润49.0亿美元，市场预估51.8亿美元；第一季度核心每股收益1.99美元，市场预估2.10美元。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺华Q1销售净额131.1亿美元，不及市场预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","IE00BFTCPJ56.SGD","BK4007","IE0002141913.USD","BK4588","BK4578","LU0070302665.USD","LU0320765489.SGD","BK4532","IE0009355771.USD","IE00BJT1NW94.SGD","LU0208291251.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4585","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115331145","title":"由于仿制药冲击严重，诺华一季度利润未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1115331145","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115331145?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:18","pubTimestamp":1777353502,"startTime":"0","endTime":"0","summary":"瑞士制药商 $诺华(NVS)$ 诺华（Novartis）周二公布，其第一季度核心营业利润低于市场预期，原因是其畅销心脏药物Entresto面临美国仿制药竞争，对销售造成压力。经特殊项目调整后的季度集团营业利润为49亿美元，低于Visible Alpha引用的分析师平均预期约51亿美元。","market":"us","thumbnail":"https://community-static.tradeup.com/news/374dbbb7be17d6f7bf0b1b2658569853","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/374dbbb7be17d6f7bf0b1b2658569853"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ca0e3dea87604e6a95a3bf5695c5bcab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"诺华第一季度利润受美国仿制药冲击而下滑","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":0.002},{"period":"1month","weight":0.0528},{"period":"3month","weight":0.0169},{"period":"6month","weight":0.1101},{"period":"1year","weight":0.2859},{"period":"ytd","weight":0.139}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.2047},{"period":"ytd","weight":0.0965}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日根据瑞士法律注册成立，为股份公司。公司是一家创新医药公司，从事研究、开发、制造、分销、营销和销售范围广泛的医药产品。它专注于核心治疗领域，包括心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.007884},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.004502},{"month":3,"riseRate":0.5,"avgChangeRate":-0.002232},{"month":4,"riseRate":0.692308,"avgChangeRate":0.016763},{"month":5,"riseRate":0.692308,"avgChangeRate":0.0095},{"month":6,"riseRate":0.592593,"avgChangeRate":0.013169},{"month":7,"riseRate":0.703704,"avgChangeRate":0.011058},{"month":8,"riseRate":0.423077,"avgChangeRate":0.001152},{"month":9,"riseRate":0.692308,"avgChangeRate":0.009673},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.013123},{"month":11,"riseRate":0.615385,"avgChangeRate":0.016411},{"month":12,"riseRate":0.692308,"avgChangeRate":0.020635}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}